HIV/AIDS non-infected pre exposure prophylaxix - HPTN083

This study will evaluate the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW).

Location: REDI (East Bay)

Please contact Jamie Carroll-Mandelk MandelJ@sutterhealth.org about HPTN083

Principal Investigator

Jeffrey H. Burack, MD

Recruitment Status

Please note that trial statuses change frequently. For the most up-to-date information, please contact the Research Department at 510.204.4155.

Start Date

November 03, 2016